Navigation Links
Cancer treatments in phase 3 trials successful up to half of the time
Date:3/24/2008

CHICAGO About one-fourth to one-half of new cancer treatments that reach assessment in phase 3 randomized clinical trials are eventually proven successful, according to a report in the March 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Cancer remains the second leading cause of death in the United States, but continuous improvements have been made in survival and other outcomes, according to background information in the article. To a large extent, this has occurred through the introduction of new treatments tested in clinical trials, with randomized controlled trials (RCTs) widely considered to be the most reliable method of assessing differences between the effects of health care interventions, the authors write. Cancer is the only disease for which the National Institutes of Health has consistently funded a cooperative clinical trial infrastructure. Despite this investment, little is known about the proportion of clinical trials that have led to the discovery of successful new treatments.

Benjamin Djulbegovic, M.D., Ph.D., of the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, and colleagues extracted data from all completed phase 3 randomized clinical trials conducted by the National Cancer Institute cooperative groups since their inception in 1955. A total of 624 trials involving 216,451 patients were analyzed.

Overall, 30 percent of the trials had statistically significant results; in 80 percent of those cases, new treatments were superior to established protocols. The original researchers reported that the risk-benefit ratio favored new treatments in 41 percent of comparisons, while standard treatments were favored in 59 percent of comparisons.

The real effects of new treatments compared with standard treatments in terms of patient outcomes such as survival is best measured by quantitative pooling of data, the authors write. When done this way, new treatments are, on average, found to be slightly superior to standard treatments, with a 5 percent relative reduction in the death rate. This, of course, should not be understood as the average effects of new discoveries being equally spread among all patients. In 15 percent of the trials, breakthrough therapies were discovered; in 2 percent of the cases, these reduced the death rate by more than 50 percent.

In conclusion, society has received a good return on its investment in the cooperative oncology group system, which funds the trials, the authors write. The public can expect that about 25 percent to 50 percent of new cancer treatments that reach the stage of assessment in randomized clinical trials will prove to be successful. This pattern of successes has become more consistent over time. However, our results also indicate that the absolute number of discoveries might be improved if the proportion of inconclusive trials is reduced.


'/>"/>

Contact: Nancy Johnson
813-745-1478
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career Step ... Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The free ... will be presented by Captain Rommie Duckworth, LP, a career fire captain as well ...
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan Pediatric Dentistry and ... its patients on Long Island, New York. , Holistic dentistry puts dental ... one of the biggest trends in dentistry today. , Dentist Dr. Marc ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, Inc., http://www.FiberstarIngredients.com ... food and beverage industry offers Citri-Fi®, a natural citrus fiber, to improve beverage ... process. As a result, labels need to deliver simple, transparent and clear messaging. ...
(Date:5/23/2017)... New York City (PRWEB) , ... May 23, ... ... Record (EHR), Population Health and Clinical Integration company, announced today that its ... Patient-Centered Medical Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards ...
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the ... sectors, today announced the winners of its 3rd Annual ELITE Awards. The ELITE ... people in the healthcare industry today. , Out of more than 500 submissions, ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... May 5, 2017   Provista , a proven leader ... 200,000 customers, today announced Jim Cunniff as the ... executive and business experience to Provista, including most recently serving ... California . He assumed his new role ... a great fit for Provista," says Jody Hatcher , ...
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
Breaking Medicine Technology: